Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4239 - The prognostic significance of infiltrating lymphocytes in resectable pancreatic ductal adenocarcinoma in untreated versus neoadjuvant treated patients.

Date

09 Sep 2017

Session

Poster display session

Presenters

Jennifer Goldstein

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

J.B. Goldstein1, D. Chatterjee2, M. Zaid3, B. Chaudhury3, D. Elganainy2, D.M. Halperin1, R. Nejati2, H. Wang1, M.H. Katz4, J.E. Lee4, J. Fleming4, J. Rodriguez Canales5, J. Blando5, I.I. Wistuba5, A. Maitra2, R.A. Wolff1, H. Wang2, G.R. Varadhachary1, E. Koay3

Author affiliations

  • 1 Gastrointestinal Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 2 Pathology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 3 Radiation Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 4 Surgical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 5 Translational Molecular Pathology, MD Anderson Cancer Center, 77030-4095 - Houston/US
More

Resources

Abstract 4239

Background

Tumor microenvironment plays an important role in chemoresistance and tumor progression of PDAC. The role of tumor infiltrating lymphocytes in treated PDAC remains unclear. This study examines the distribution of intratumoral lymphocytes and their correlation with survival and clinicopathologic factors in patients with resected PDAC.

Methods

We studied 75 patients who completed pancreaticoduodenectomy (PD) plus neoadjuvant therapies between 1999 and 2007. Neoadjuvant therapies included Gemcitabine + nab-paclitaxel and FOLFIRINOX or chemoradiation. Immunohistochemistry (IHC) for CD4, CD8, and FOXP3 were performed on resection specimens, which contained two representative slides from each patient. Digital images of IHC-stained slides were obtained at 20 x magnifications using a whole slide scanner (ScanScope, Aperio AT Turbo). Tumor regions were hand-annotated on whole slide images and computer assisted quantitative analysis was performed using Aperio’s ImageScope software. The tumor infiltrating lymphocytes were calculated as the percentage of positive staining area vs the total tumor area. Cox Regression analysis was performed for univariate and multivariate analysis.

Results

The average percentage for CD4, CD8 positive cells were 6.08 ± 7.76, 2.84± 3.64, respectively in the treated cohort. Using the 50 percentile value as a cutoff, patients with high CD4+ lymphocytes had better disease free survival vs low CD4 positive lymphocytes (HR 0.234, P = 0.0031). There were no significant correlations between CD 4+, CD8+, CD68+, Granzyme B+, KP-1+, FOXP3+ lymphocytes and overall survival (p > 0.05). In multivariate analysis, neither CD4+ lymphocytes (HR: 0.49, P = 0.004), CD 8+ or CD 4/CD 8 ratio were independent prognostic factors for overall survival (See table).Table:

735P

VariableUnivariate Analysis (DFS)Mulitivariate Analysis (DFS)
P-valueHR (95% CI)P-valueHR (95% CI)
CD 4 High vs. Low (Reference)0.0030.234 (0.073-0.627)0.5100.553 (0.094-3.220)
CD 8 High vs. Low (Reference)0.0210.366 (0.146-0.858)0.6950.752 (0.170-2.919)
CD 4/CD 8 ratio High vs. Low (Reference)0.0460.393 (0.141-0.983)0.1120.344 (0.084-1.281)
CD 68/CD 4 ratio High vs. Low (Reference)0.0850.424 (0.123-1.114)0.2610.521 (0.135-1.561)

Conclusions

Our study showed that the presence of high CD4+ and CD8+ lymphocytes is an independent prognostic factor for disease free survival in resectable neoadjuvant treated PDAC patients. We believe that neoadjuvant chemotherapy induces an enhanced immune response that may contribute to improved survival outcomes. Results are currently being analyzed looking at tumor infiltrating lymphocytes in resectable PDAC patients receiving receiving surgery alone.

Clinical trial identification

Legal entity responsible for the study

MD Anderson Cancer Center

Funding

None

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.